Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
A seizure typically lasts 1 to 2 minutes, but a seizure cluster can last for hours. Seizure clusters affect a small number of people, but if left untreated can cause serious consequences. #RallyForRare https://t.co/yrKQUMwz72
— UCB News (@ucb_news) 27.02.2020 -
At UCB, we aim to create genuine value and improve the lives of those impacted by severe diseases, including #rarediseases. Our Late Indications and Market Strategy Lead, Blair Robertson, weighs in on this approach. https://t.co/9D3CCK1lXD #RallyForRare h
— UCB News (@ucb_news) 26.02.2020 -
#Progressivesupranuclearpalsy (PSP) is a rare and severe neurodegenerative brain disorder for which there is currently no cure. Find out more here: https://t.co/FzaFgpE2RR #RareDiseaseDay https://t.co/iAb6AZBu1A
— UCB News (@ucb_news) 26.02.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
